FDA green-lights wider use of Alere's rapid influenza test; NICE gives thumbs-down to Millennium Pharma's drug for Crohn's;

@FiercePharma: Whistle-blowing Bayer sales rep wins again in wrongful termination suit. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Bayer drafts 'Community' star to launch cult-favorite hangover cure in U.S. More | Follow @CarlyHFierce

> The FDA gave its blessing for wider use of Alere's ($ALR) rapid molecular test for influenza. Story

> U.K. cost gatekeeper NICE issued draft guidance recommending against the use of Millennium Pharmaceuticals' Entyvio drug for Crohn's disease. More

> Teva Pharmaceutical ($TEVA) launched its generic copycat of Novartis' ($NVS) blood pressure med Diovan in the U.S. Story

> Anacor's ex co-founder David Perry has signed onto Symbiota, a Cambridge, MA-based start-up agricultural plant health company, as its president and chief executive officer. More

> Aveo Oncology said it plans to eliminate two-thirds of its workforce as part of a corporate restructuring effort. Story

Medical Device News

@FierceMedDev: Graphene 'flying carpet' strips deliver two #cancer drugs, each to a different cell target. Article | Follow @FierceMedDev

@EmilyWFierce: Cancer Genetics gets nod to offer cancer testing in California. Story | Follow @EmilyWFierce

> FDA clears pivotal trial for permanent use of artificial heart. Story

> Shockwave's energy-delivering angioplasty balloon for PAD receives CE mark. Article

> New technology can spot cavities early, but is that necessary? News

Biotech News

@FierceBiotech: Aveo guts its R&D operation, cutting two-thirds of its payroll. Item | Follow @FierceBiotech

@JohnCFierce: Eyeing an IPO, Genkyotex banks a $21M round for PhII study -- NOX inhibition. Story | Follow @JohnCFierce

@DamianFierce: Another roughly $65M in biotech VC announced today, making for a three-day total nearing $700M. | Follow @DamianFierce

> Alkermes sees PhII promise for schizophrenia drug that doesn't pack on pounds. Story

> Pfizer, NEA orphan drug project launches its first biotech on PhII/III threshold. Report

> Zafgen's promising obesity drug comes through in another midstage trial. More

> Blend banks $21M for its nano-assisted cancer drugs. Article

Drug Delivery News

> Palo Alto pain management startup Carbylan vies for $86M IPO. Article

> Blend Therapeutics receives $21M in Series B round. Item

> Australia's EnGeneIC receives $10M in Series B round for studies of anticancer delivery tech. News

> Graphene 'flying carpet' strips deliver two cancer drugs, each to a different cell target. Report

> NeuroDerm's subcutaneously delivered alternative to oral levodopa shows promise in Parkinson's trial. More

Diagnostics News

> HTG Molecular Diagnostics mulls $60M IPO for next-gen profiling technology. Report

> Illumina blazes into 2015 with plans for new California campus. News

> Molecular Dx maker CombiMatrix wins a battle in insurance fraud lawsuit. Article

> Cancer Genetics gets nod to offer cancer testing in California. More

> Israel's Itamar looks to China, Canada and beyond for growth. Story

Pharma Marketing News

> Do rival DTC campaigns help your own brand? Yes, a study shows--up to a point. Report

> FDA's marketing police wrote only 10 tickets in 2014. Story

> Whistle-blowing Bayer sales rep wins again in wrongful termination suit. More

> Pfizer complains, advertising watchdog acts against Novartis Theraflu promo. Article

> Bayer drafts 'Community' star to launch cult-favorite hangover cure in U.S. News

And Finally… Pharmaceuticals and chemicals from personal care products could produce harmful toxins in swimming pools, according to a new study. More

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.